scispace - formally typeset
Open AccessJournal ArticleDOI

Geographic and Genomic Distribution of SARS-CoV-2 Mutations

Daniele Mercatelli, +1 more
- 22 Jul 2020 - 
- Vol. 11, Iss: 11, pp 1800-1800
Reads0
Chats0
TLDR
The analysis may facilitate custom-designed antiviral strategies based on the molecular specificities of SARS-CoV-2 in different patients and geographical locations and shows the prevalence of single nucleotide transitions as the major mutational type across the world.
Abstract
The novel respiratory disease COVID-19 has reached the status of worldwide pandemic and large efforts are currently being undertaken in molecularly characterizing the virus causing it, SARS-CoV-2. The genomic variability of SARS-CoV-2 specimens scattered across the globe can underly geographically specific etiological effects. In the present study, we gather the 48,635 SARS-CoV-2 complete genomes currently available thanks to the collection endeavor of the GISAID consortium and thousands of contributing laboratories. We analyzed and annotated all SARS-CoV-2 mutations compared with the reference Wuhan genome NC_045512.2, observing an average of 7.23 mutations per sample. Our analysis shows the prevalence of single nucleotide transitions as the major mutational type across the world. There exist at least three clades characterized by geographic and genomic specificity. In particular, clade G, prevalent in Europe, carries a D614G mutation in the Spike protein, which is responsible for the initial interaction of the virus with the host human cell. Our analysis may facilitate custom-designed antiviral strategies based on the molecular specificities of SARS-CoV-2 in different patients and geographical locations.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Genomic evidence for reinfection with SARS-CoV-2: a case study.

TL;DR: The findings suggest that the patient was infected by SARS-CoV-2 on two separate occasions by a genetically distinct virus, suggesting that previous exposure to Sars-Cov-2 might not guarantee total immunity in all cases.
Journal ArticleDOI

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.

TL;DR: The challenges in assessing the efficacy of candidate SARS-CoV-2 vaccines are explored, the caveats needed to interpret reported efficacy endpoints are discussed, and insight is provided into answering the seemingly simple question, “Does this COVID-19 vaccine work?”
Posted ContentDOI

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

TL;DR: The LY-CoV1404 (also known as bebtelovimab) is a highly potent, neutralizing, SARS CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient sample, obtained approximately 60 days after symptom onset as mentioned in this paper.
References
More filters
Journal ArticleDOI

The proximal origin of SARS-CoV-2.

TL;DR: It is shown that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus, and scenarios by which they could have arisen are discussed.
Journal ArticleDOI

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

TL;DR: The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route and work that may provide a basis for development of anticoronaviral drugs.
Journal ArticleDOI

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.

TL;DR: The crystal structure of the C-terminal domain of SARS-CoV-2 (SARS- coV- 2-CTD) spike (S) protein in complex with human ACE2 (hACE2) is presented, which reveals a hACE2-binding mode similar overall to that observed for SARS -CoV.
Related Papers (5)